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Renin-angiotensin system (RAS), controlled by angiotensin II octapeptide signaling at angiotensin AT~1~R and AT~2~R receptors, plays a key role in regulating cardiovascular and electrolyte homeostasis. The more recently discovered "protective arm" of RAS, which involves several other angiotensin peptide isomers and signals largely via AT~2~R (as well as proto-oncogene MAS receptor), has also been implicated in a variety of tissue-protective functions in the human body. While AT~1~R has a well-understood canonical G protein-coupled receptor (GPCR) signaling via G protein and arrestin and is a prominent target of blockbuster antihypertensive drugs---angiotensin receptor blockers (ARBs), also known as "Sartans" ([@bib9])---the AT~2~R sibling has been notorious as an "enigmatic" receptor ([@bib5]).

During the 25 years since its discovery, AT~2~R has been implicated in numerous physiological functions with great potential for drug discovery ([@bib4]). AT~2~R activation by AngII is believed to directly oppose AT~1~R signaling, mediating vasodilatory effects and reducing blood pressure. In addition, many studies show that AT~2~R activation by Ang(1-9) and, potentially by Ang(1-7), confers protective, antifibrotic, and anti-inflammatory properties in a variety of tissues including the heart, lung, kidney, and brain ([@bib4]). Intriguingly, these protective peptides are produced by angiotensin converting enzyme 2 (ACE2), which is exploited as a host factor by SARS and COVID-19 viruses, aggravating lung tissue damage often caused by these dangerous coronavirus infections. While AT~2~R is more abundant in the fetus and neonate, where it is believed to be involved in vasculature growth and neural development, the receptor retains expression in several adult tissues and is greatly induced in tissues undergoing repair. The initial interest in the protective properties of AT~2~R arose from clinical studies showing that ARBs can be superior to other antihypertensive drugs in the prevention of stroke, even with no differences in blood pressure, and that one of the protective mechanisms was mediated by AT~2~R ([@bib8]). As such, AT~2~R-selective ligands, e.g., Ang(1-9) peptide or small molecule agonist C21, are being extensively tested in preclinical studies for acute lung injury and fibrosis, kidney fibrosis, Alzheimer's disease, and stroke. Notably, AT~2~R antagonism in the peripheral nervous system also shows promise in potential clinical applications as a treatment for chronic neuropathic pain. Small molecule antagonist EMA401 showed efficacy in treating neuropathic pain in phase II clinical studies ([@bib6]), until the development of this candidate was stopped due to off-target side effects.

On the other hand, translation of these very promising findings into clinical therapies has been hampered by very puzzling functional mechanisms ascribed to AT~2~R activation on the molecular and cellular levels, as well as by the very limited toolchest of AT~2~R-selective drug-like compounds. AT~2~R is believed to bypass canonical G protein- and arrestin-mediated signaling, activating instead downstream effectors such as ERK1/2 and NOS ([@bib5]). Several other downstream pathways have been suggested, but the mechanistic understanding of AT~2~R signaling is still far from obvious. Moreover, on the cellular level, a recent discovery implicates AT~2~R expressed in macrophages, but not in neurons themselves, in neuropathic pain induced by locally released AngII, adding a new twist to the development of AT~2~R-mediated pain remedies ([@bib7]).

When the first structure of AT~2~R was solved in 2017 ([@bib10]), the receptor definitely lived up to its "enigmatic" reputation. Most strikingly, the antagonist-bound structures of AT~2~R consistently showed all the hallmarks of GPCR active state, including all microswitches and helical rearrangements on the intracellular side of the receptor, including an outward shift of TM6 and inward shift of TM7 ([@bib3]). This conformational arrangement was the same for different antagonists and different crystal packing of AT~2~R and drastically differed from its sibling AT~1~R, which shows a canonical inactive state with antagonists and canonical active state with agonists.

Moreover, this antagonist-bound "active state" in AT~2~R came with a catch---helix 8, instead of sticking to the intracellular surface of the membrane as in other GPCRs, is switched to a previously unknown position, bundling to helices TM5 and TM6 and thus hindering possible interactions of AT~2~R with G protein or arrestin. This position of helix 8 was corroborated by strong interaction interface with TM5/TM6, as well as with molecular dynamics simulations showing that even when pulled slightly away, helix 8 returned to its blocking position. Furthermore, the AT~2~R structure with partial agonist derivative of AngII, \[Sar1, Ile8\]-AngII, was also found in a similar active-like state ([@bib1]), though completely lacking electron density for helix 8 and thus suggesting high conformational flexibility of this helix.

In this issue of *Structure*, the structure of AT~2~R complex with endogenous AngII peptide and a stabilizing FAB antibody from the So Iwata group reveals a number of intriguing details and insights into the receptor workings ([@bib2]). In general, it shows the same overall active-state conformation as in previous complexes with small molecule antagonists ([@bib10]) and the partial agonist analog of AngII ([@bib1]) ([Figure 1](#fig1){ref-type="fig"} ). But it also gives insight into what differentiates the full agonist binding in terms of receptor conformation. First of all, the differences at the bottom of the ligand-binding pocket are notable. The terminal Phe8 side chain of AngII (but not Ile8 of the partial agonist or the small molecule antagonist) is pushing Met128 side chain to change conformation where it impinges on Trp269, one of the key residues in the activation mechanism. This reshaped binding pocket may provide a better template for structure-based design of full AT~2~R agonists, though small molecules like C21 may further adjust the orthosteric pocket.Figure 1Comparison of AT~2~R Conformers(A) Superimposition of crystal structures in complex with antagonist (compound 1, PDB: [5UNF](pdb:5UNF){#intref0010}, green ribbon), partial agonist (\[Sar1,Ile8\]-Ang II, PDB: [5XJM](pdb:5XJM){#intref0015}, magenta ribbon), and full agonist (AngII, PDB: [6JOD](pdb:6JOD){#intref0020}, yellow ribbon).(B) Hypothetical energy profile for the conformational change in helix 8.

The most intriguing, though, is the conformation of helix 8 resolved in this agonist-bound structure. Unlike the antagonist-bound conformation, where helix 8 was blocking the intracellular site of G protein binding, or partial agonist structure, where helix 8 was completely unresolved, the new agonist structure reveals helix 8 in the canonical membrane-bound position, where it does not obstruct the intracellular pocket. These observations and comparative analysis of the structure suggest that the AT~2~R resting state naturally prefers active-like conformation, but with downstream signaling blocked by helix 8; partial agonists partially unblock it by destabilizing the TM6-bound conformation of helix 8, while full agonists further stabilize helix 8 in the membrane-bound state, allowing full downstream signaling. One has to be cautious in jumping to conclusions here, though, as noted by Asada et al., and further studies are needed to confirm that this helix 8 observation is not an artifact of crystal packing.

There are at least three layers of the puzzle to break the enigmatic code of AT~2~R function, which remain to be resolved by further structural, biochemical, and computational studies ([Figure 2](#fig2){ref-type="fig"} ):(1)On the molecular level, if AT~2~R signaling is not G protein and β arrestin mediated, what are the actual cognate proteins that recognize AT~2~R active state, and how are they connected to the downstream signaling via ERK1/2 and NOS?(2)On the physiological level, what is the functional and physiological difference between the three known endogenous AT~2~R ligands: AngII, Ang(1-9), and Ang(1-7)? Do they confer similar signaling profiles or are they differentially biased to some downstream pathways against the others? How does AT~2~R signaling interact with other RAS pathways?(3)On the pharmacological level, how do small molecule drug candidates like agonist C21 and antagonist EMA401 bind AT~2~R, inducing activation or blockade, and how can the structural information on these ligands be used to rationally design new, more potent and selective agonists and antagonists? Figure 2Layers of AT~2~R Signaling EnigmaSeveral questions at physiological, molecular, and pharmacological levels remain to be answered to break the enigma code of AT~2~R function.

The answers to such questions require multidisciplinary studies including further structural and molecular dynamics analysis of AT~2~R complexes, expansion of the repertoire of AT~2~R-selective agonists and antagonists, and thorough characterization of their function. The rewards to breaking the AT~2~R enigma code will be high, as it would greatly facilitate the discovery of new AT~2~R-mediated therapies for major chronic conditions like neuropathic pain, stroke, Alzheimer's disease, and cancer.
